Clinical trial
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV)…
NCT02747927 · Takeda, Industry · Completed
Key facts
| NCT number | NCT02747927 |
|---|---|
| Title | Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children |
| Official title | Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 - 16 Years Old |
| Acronym | TIDES |
| Lead sponsor | Takeda, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Healthy Volunteers |
| Intervention type | Biological, Drug |
| Interventions | Placebo, Tetravalent Dengue Vaccine (TDV) |
| Enrollment | 20,099 |
| Start date | Apr 26, 2016 |
| Primary completion | Jul 11, 2018 |
| Completion | Jun 28, 2024 |
| First posted | Apr 22, 2016 |
| Last update posted | Nov 19, 2025 |
| Countries | Brazil, Colombia, Dominican Republic, Nicaragua, Panama, Philippines, Sri Lanka, Thailand |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: